Drug Discovery Technology Alert. Novel Vaccine Treatment for Meningococcal Disease Obtains FDA Clearance; Nasal Testosterone Replacement Therapy to Treat Male Hypogonadism; Injection Therapy to Control Hypocalcemia in Patients with Hypoparathyroidism

USD 950

* Required Fields

USD 950

PAY BY INVOICE

Be the first to review this product

This issue profiles a vaccine treatment for meningococcal disease that obtains FDA clearance, a nasal testosterone replacement therapy to treat male hypogonadism, and an injection therapy to control hypocalcemia in patients with hypoparathyroidism.

Table of Contents

Drug Discovery Technology Alert. Novel Vaccine Treatment for Meningococcal Disease Obtains FDA Clearance; Nasal Testosterone Replacement Therapy to Treat Male Hypogonadism; Injection Therapy to Control Hypocalcemia in Patients with HypoparathyroidismIn This Issue1. NASAL TESTOSTERONE REPLACEMENT THERAPY TO TREAT MALE HYPOGONADISM2. IRON REPLACEMENT DRUG THERAPY FOR PATIENTS SUFFERING FROM CHRONIC KIDNEY DISEASE3. NOVEL VACCINE TREATMENT FOR MENINGOCOCCAL DISEASE OBTAINS FDA CLEARANCE4. INJECTION THERAPY TO CONTROL HYPOCALCEMIA IN PATIENTS WITH HYPOPARATHYROIDISM5. NOVEL DRUG THERAPY TO TREAT PARKINSON’S DISEASE ANNOUNCED6. BREAKTHROUGH DRUG TO REDUCE STROKE RISK AND VENOUS THROMBOEMBOLISM ASSOCIATED WITH ATRIAL FIBRILLATION7. FDA-APPROVED DRUG TO TREAT GASTRIC CANCER8. PATENTS ON THERAPEUTIC AGENTS TO TREAT HYPOGONADISM




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.